SCRS Talks
SCRS Talks, hosted by the Society for Clinical Research Sites (SCRS), is a platform for clinical research industry professionals to hear about valuable information shaping the research industry today. These short interviews will provide new perspectives and insights on pressing topics, current events, and the research community.
SCRS Talks
Why Early Site Engagement Changes Everything
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Site engagement often shows up only after a study is already in trouble. In this episode of SCRS Talks, Jimmy Bechtel sits down with Julie Wilhjelm, Senior Director of Site Strategy and Engagement at Novotech, to talk about why it should be built into how studies are planned and run from day one.
They cover what separates real engagement from checkbox outreach, how early feedback during feasibility and protocol design can head off costly amendments, and why trust and responsiveness give CROs a real edge with the sites they work with. Julie also gets honest about the revolving door of site contacts, what it costs everyone, and why continuity is so hard to solve at scale.
If you work with sites, or you are one, this one is worth a listen.
Hello, and welcome to SCRS Talks, provided by the Society for Clinical Research Sites. I'm Jimmy Bechtel, the chief site success officer with the Society, and today I'm lucky to be joined by Julie Wilhjelm, who is the current senior director of site strategy and engagement with Novotech. Julie's Here to talk with us about how important site engagement is, especially early site engagement, and how we build that in to just our normal day-to-day processes as an organization, not making the sites an afterthought, not making the sites wait for that to provide that feedback, but really building it into our day-to-day as we work so closely together. But before we get into the topic, I, Julie, want to allow you just a few minutes to introduce yourself. So please.
Julie WilhjelmThanks for having me, Jimmy. I really appreciate the opportunity to come on and talk about my favorite topic. I'm Julie Wilhjelm senior director of site strategy and engagement at Novotech. We are a full-service CRO and scientific advisory partner working with biotech and small to mid-size pharmaceutical companies, helping to advance drug development. We have a global footprint across Asia-Pacific, North America, and Europe, and we give our clients an accelerated path, bringing life-changing therapies to market. As for myself, I've spent over 20 years in clin ops, in study execution and portfolio oversight. But for the last five years, I've had the opportunity to focus on building out site relationship functions and making sure sites have a real seat at the table in how our studies are planned and operationalized. I truly believe studies succeed when sites succeed, and as you'll be able to tell, I'm very passionate about early site engagement, bringing that site voice into protocol design and feasibility so our trials are more predictable and better for everyone involved, especially our patients
Jimmy BechtelExcellent. Julie, you are definitely qualified to talk about how we can engage sites better and, this is a... It's always a hot topic. It's an ask, it's a demand that the sites have, and so I'm really excited to explore how NovaTech has really built this into what they do. And site engagement as, as we've stated, alluded to here, is oftentimes treated as this reactive fix, We were well down the path we're working on the trial, we've selected sites, patients are coming in, and then something happens. We're starting to notice deviations or certain aspects of the protocol we're just getting a lot of pushback on, or patients aren't executing visits, and then we involve the sites, which is obviously far too late, and may be something that could have been prevented had we engaged them earlier. So talk to me about why it should be structured as a discipline that starts early, either during feasibility or protocol development, or maybe even earlier if possible, rather than, again, retrospectively after problems start showing up.
Julie WilhjelmI think you've just hit on several of the reasons why, Stop Me if you've heard our engagement shows up when something's already gone off the rails, Enrollment's lagging, and all of a sudden sites are getting called every week, and we're asking why. "Why are your patients not coming in? Can you send me your pre-screening logs?" Or after a monitoring visit, there is an issue that, could have been caught if maybe we'd been paying closer attention all along. But, either way, or with the examples that you even mentioned, that's site engagement, but we're acting as damage control, but not as a discipline. And if we were, treating this as discipline, that's built into how our studies are planned and run, and not when we reach for it once our performance is dipping. Most of what shapes, sites' experience is already in motion, like you said, before that first patient is enrolling, so before that protocol is finalized. Feasibility and site selection are usually treated as data gathering. Can the site deliver? How fast can they deliver? Instead of starting it at the actual relationship. But if we're contacting our sites only once enrollment lags, we're starting from behind. But if we're engaging our sites early, they're already invested, So we should be engaging our sites early when they can tell us about the protocol, When they can tell us about that demanding visit schedule or the narrow eligibility criteria, or, maybe it's that the patients are gonna have a hard time coming in. Maybe we could change the visit schedule to allow for home health. If we can catch that early on in that feasibility conversation, that's a fix. If we catch that same issue discovered after activation, that would mean a protocol amendment, That means a big cost of waiting, and that ripples across every site on the study, sometimes across regions, and it affects those patients already consented. So we really need to start this as a structured discipline instead of being reactive.
Jimmy BechtelA lot of excellent examples there, Julie, and reasoning behind why it's so important that we do this. And I know we'll talk a little bit about some of the whys behind this, but thank you for sharing some of the perspective, really cultural differences, is one way you could look at them, but really the value in bringing this in early. So Julie, what then is the real difference between outreach and just asking them questions or, having a touch point with them and true site engagement? I guess in other words, what operational pieces and responsiveness and consistent communication, things along those lines actually build trust and turn into, again, what we are coining, true site engagement?
Julie WilhjelmSo I guess I like to think a bit about any relationship, you have in your life that works, You could be having a relationship. Is it that friend that you have that's just blasting you with texts, or is it maybe you consider a good friend that checks in, that genuinely wants to know, like, how you're doing, It's the quality of the contact that you're having. So outreach, site outreach is activity, It's the emails. It's the check-ins. It's the meetings. But what is the quality that we have with our sites in the emails? Are we just checking a box and sending off weekly emails because that's work, what we're supposed to do? Are we having those site check-ins because it's something that we're supposed to do? Are we truly engaging with sites and making it easier for you to do your sites well, to succeed? Sites are already balancing patient care, recruitment, data entry, site contracts, amendments, all these different changing regulatory requirements, multiple studies at once. We know you don't have just one study to do. We'd like to think that you just have our study, but we know the reality. So like I said, in any relationship, just adding a touch point doesn't make it stronger, It doesn't make it engagement. Sometimes it just adds more work to your plate. But the value is the value in any really solid relationship and the trust comes in when can they get a quick answer from us, like, when you really need one, There's a question on the protocol, What does inclusion criterion three really mean? Who to call? We know at a CRO you can have several different touch points. What's the real one that you need to call when you have a certain question? Who's really gonna listen when something isn't working? Who's gonna respond? Who's gonna be consistent? And really the most important, who's gonna follow through on what you say you're going to do? And then executing matters as much as the intent. Startup documents, are they accurate the first time? Is a process working, as we say it's going to work? That sites aren't left to catch those mistakes when they happen. And that we're not waiting for it to become a bigger issue, The conversations need to happen early. So the trust isn't in those, those big moments, Like in building up to the SIV. It's in those really small everyday ones. So like in any relationship, the trust is in those, those small, how are, how are things really going texts, emails, calls instead of those just checkbox moments, right? That's when the trust really happens
Jimmy BechtelExcellent points, Julie. And what I took away from that really is it's, you said it right there at the end, it's taking the relationship beyond just a simple transactional one. It's actually building a relationship and taking, as we said, these outreach instances, these one-offs, these checkbox opportunities and building, effective relationship through a lot of the things that, that you mentioned there. Being responsive, the consistent communication, following through and following up with what's being done there and building that into the core of how you and your teams operate and execute on those relationships is really a just a shift in perspective that we see unfortunately not a lot of organizations maintain. So it's great to see that there are, again, a partners in existence that do prioritize those kinds of things. So Julie, then What's the business impact when Site engagement is done well, We know that we can think about things or allude to potentials like timelines and enrollments and long-term partnerships, but maybe break some of those down or explain what that really means and give us a little bit of the why.
Julie WilhjelmSo I think there might be some obvious impacts, Like you've got deliverables and those faster timelines if site engagement is done well. The enrollment piece and the business impact. But, I think that those are what you might think of as, as low-hanging fruit. Like everybody wants that quick, first site activated, And we obviously want enrollment. But we also wanna look at like data quality, And quality across the board, and data entry when site engagement is done well. We know that Again, stop me if you've heard this, but you get a call that we've got a data crunch, and we need the data entered at least maybe not within five business days, but can you please do it in three business days? If we're really engaging with sites and you've got your trust in us, which study are you gonna choose, The study where you've really got that trust and that solid relationship, or one where we're just being transactional? you're gonna go where we've got that trust and that true relationship, so that's a true business impact, And that's a long-term partnership value that can last across multiple studies. Because ideally we've all got these, long-term impacts, and we're placing multiple studies, and sponsors are placing partners, and we're placing partnership studies across all of these sites. So that's a very long-term business impact we have. And then the relationship is just gonna compound. So if we've worked with the site long term, we're gonna understand each other's expectations. We understand capabilities and therapeutic experience. So that's gonna shorten a learning curve the next time we work together, So maybe we won't have to send out those very tedious feasibility questionnaires. One thing that we're doing at Novotech is not having to send out, long feasibility questionnaires. We're just hoping to pick up the phone and say, "All right. We know that you have certain capabilities at your site. We've got this certain protocol. Do you have the interest, and can you complete, these five protocol-specific capabilities?" So because we've worked with you, and we don't need to have this really long learning curve, and it kinda changes that conversation, right? And then we can get into that- bigger conversation about what are you seeing in this space? Like, where do you wanna grow? In that kind of partnership conversation instead of just being really transactional. And then I guess if I can come back to that feasibility conversation, we kinda touched on it in an earlier answer. If we look at visit burdens and eligibility criteria before a protocol locks that can go across all sites on a study, So if we're engaging early, and we've got that really solid site engagement, we can catch a protocol amendment before maybe a protocol locks, It'll affect every single site and we catch those fixable issues at that feasibility stage versus discovering it after activation
Jimmy BechtelThanks, Julie. Again, a lot of really great insights there and opportunities. I think you hit it on the head when you alluded to a site who has multiple potential trials, multiple potential partners there, having to choose between two and resources. They're going to choose the relationship and their time dedicated to the one that they have a stronger relationship with. That's the bottom line there, and that translates directly to the quicker and more efficient execution of your clinical trial timelines. So I think it's a major I would say competitive edge that a CRO specifically could have with their site partners when they dedicate themselves to stronger relationships. I think it's a, an, an excellent point. And, Julie, moving to our final question here before we begin to close. We know that sites are often dealing with a revolving door of contacts over a study's life cycle, right? CRAs come and go, et cetera, but what does that fragmentation actually end up costing us? And why is continuity so hard for sponsors and CROs to really solve at scale? What's going on here? Why, and then maybe what's the solution in your eyes that we might think about and be able to advise some of our other partners that might be listening on how we can do this?
Julie WilhjelmI think this is probably the biggest question or one of the biggest questions in our industry, right? Those site relationships often live inside those individual functions, So startup, monitoring, project management. They're not owned end to end. So solving that continuity, unfortunately it's just not about having better intentions. It's just that organizational design choice that we have in this industry. And one thing I really credit I credit a lot of things to sites, but sites have tried, and they have come so far in matching their own roles to sponsor and CRO structures to just create some of that continuity on their end. But at the end of the day, sites don't have that scale to solve this alone. So I think to match that, some CROs and sponsors have really tried to meet sites where they are, but there's still that unresolved tension there. So that cost has then been those fragmented relationships, so sites are re-explaining their contents. And then we've got that institutional amnesia that we tend to have about sites' capabilities, and constraints get lost between studies and sometimes in between single sites. So it's that unsolved tension that we have that sponsors and CROs feel, and very few have solved that cleanly at scale. And so- I guess to sum up that answer, I don't know that I have an answer, but what I do want to say is this is why forums like SCRS matter. And I think that what we have found is that the continual discussions that we have I have just seen such a growth and these conversations move forward because these conversations don't happen enough, I don't think, in the industry. And closing the gap really starts with these types of dialogues about how we can move this forward and change those contacts and continue to try to solve them just to make that revolving door, like you said, at sites move forward and keep that continuity solved for them
Jimmy BechtelExcellent. Another set of really interesting and insightful points there. and I think just something for us to think about, right? As we approach this, not one solution is necessarily, to your point, gonna work here, Julie, but a series of different perspectives and approaching the relationship differently and understanding what's really important to driving that forward. So thank you and I think thank you for being here with us today and shedding some light and insight into what it looks like to have really strong site engagement and true site partnerships. So again, thank you for that, but also thank you for the conversation today.
Julie WilhjelmI really appreciate the time and the opportunity, and thank you again for the platform.
Jimmy BechtelAbsolutely. And thanks again, Julie. And for those that are listening, I also wanna make sure that you take some time to check out other site-focused resources on our website, myscrs.org, like other podcasts, webinar opportunities, and articles centered around site relationships and site engagement. But for now, thanks for listening, for tuning in, and until next time.